Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BLX 0871
Therapeutic Area : Nutrition and Weight Loss
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Biolexis Advances AMPK Agonists for Weight Loss in Preclinical Development
Details : BLX 0871 is an AMPK activator, which is being evaluated in the early-stage clinical trial studies for the treatment of obesity and Type 2 diabetes.
Brand Name : BLX 0871
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 29, 2024
Lead Product(s) : BLX 0871
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : BLX-7006
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Biolexis Reports Promising Preclinical Data for Oral Weight Loss Drug BLX-7006
Details : Oral small molecule GLP-1 agonist, BLX-7006, is being investigated in patients with obesity and type-2 diabetes, as a weight loss/management drug.
Brand Name : BLX-7006
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 12, 2024
Lead Product(s) : BLX-7006
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : BLX-7006
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Biolexis Unveils Promising Data for Oral Weight Loss Drug BLX-7006 in Studies
Details : BLX-7006 is an oral small molecule GLP-1 agonist, which is evaluated in preclinical studies to provide potential breakthroughs in the global fight against obesity.
Brand Name : BLX-7006
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 12, 2024
Lead Product(s) : BLX-7006
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery
Sponsor : Halia Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Halia and Biolexis Partner To Develop NLRP3 Neuroinflammation Therapy
Details : The collaboration successfully identified a novel brain-penetrant small molecule candidate targeting NLRP3-driven neuroinflammation by leveraging Biolexis' MolecuLern™ AI-enabled approach.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 31, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery
Sponsor : Halia Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : MLX0800
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Clarke Capital
Deal Size : $10.0 million
Deal Type : Series A Financing
Biolexis Secures $10 Million in Series A Funding to Advance Metabolic Drug Development
Details : The new funding will advance Biolexis' development pipeline which includes a range of promising metabolic drug candidates, including MLX0800, oral small molecules for the treatment of obesity and type 2 diabetes.
Brand Name : MLX0800
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 29, 2023
Lead Product(s) : MLX0800
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Clarke Capital
Deal Size : $10.0 million
Deal Type : Series A Financing
Lead Product(s) : MLX7000
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Metabolexis
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MLX7000 is a oral small molecules, which is trageted as Glucagon-like peptide-1 receptor, which is investigated for the treatment of weight loss and type 2 diabetic.
Brand Name : MLX7000
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 26, 2023
Lead Product(s) : MLX7000
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Metabolexis
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?